Researchers recently found that fixed dosing with an anti-VEGF agent eliminated disease activity—absence of both leakage and retinal fluid—in most eyes with neovascular AMD (nAMD) over the course of 52 weeks.

In the phase III VIEW 1 and VIEW 2 studies, 2,373 eyes with nAMD were treated with intravitreal aflibercept or ranibizumab. Independent, masked reading centers determined the presence of leakage and retinal fluid at baseline and weeks 24 and 52. The team assessed the relationship between leakage/fluid status and best-corrected visual acuity (BCVA) and evaluated the impact of baseline lesion type: predominantly classic (PC), minimally classic (MC) and occult.

At baseline, the investigators discovered that 95.4% of eyes had both leakage and fluid. By week 52 of treatment, they saw this number drop to 6.0%. They noted that mean BCVA gains at week 52 were greater in eyes without leakage or fluid compared with eyes with both leakage and fluid (10.3 vs. 9.2 letters). At week 52, they added that 11.6%, 15.3% and 20.1% of eyes with PC, MC and occult lesions had both leakage and fluid, respectively.

“The effect of anti-VEGF treatment on leakage/fluid status favored PC versus occult lesions,” the study authors concluded.

Moshfeghi DM, Thompson D, Saroj N. Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies. Br J Ophthalmol. December 11, 2019. [Epub ahead of print].